Protherics PLC
Notification of Major Interest in Shares
London, UK; Brentwood, TN, US; 8 January 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that notification was received today from Aviva plc
that, following the purchase of 3,738,187 Ordinary 2p shares in Protherics on 4
January 2007 (1.10% of the Company's issued share capital), Aviva plc and its
subsidiaries hold an interest in 40,095,830 Ordinary Shares (11.83%).
The shares are represented by a beneficial interest in 20,220,671 Ordinary
Shares (5.97%) and a non-beneficial interest in 19,875,159 Ordinary Shares
(5.86%).
This notification follows the Company's recent Placing and Open Offer and is
based on an enlarged share capital of 338,976,174 Ordinary Shares.
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
Protherics PLC announces Major Interest in Shares
| Source: Protherics PLC
Cheshire, UK -- (MARKET WIRE) -- January 8, 2007 --